Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 16/20 | 0.68 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.68 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26914669 | 1.00 | PTGER4 (0.68) | PTGER4PTGER2MRGPRX4PTGDRPTGER1 | |
| SCHEMBL4017242 | 0.94 | PTGER4 (0.67) | PTGER4PTGER2PTGER1 | |
| SCHEMBL691928 | 0.92 | PTGER4 (0.67) | PTGER4PTGER2MRGPRX4PTGDRPTGER1 | |
| SCHEMBL4012473 | 0.92 | PTGER4 (0.57) | PTGER4PTGER2MRGPRX4PTGER1ALDH1A1 | |
| SCHEMBL4018036 | 0.91 | PTGER4 (0.63) | PTGER4PTGER2MRGPRX4PTGDRPTGER1 | |
| SCHEMBL691884 | 0.90 | PTGER4 (0.65) | PTGER4PTGER2MRGPRX4PTGDRPTGER1 | |
| SCHEMBL5505531 | 0.90 | PTGER4 (0.65) | PTGER4PTGER2MRGPRX4PTGDRPTGER1 | |
| SCHEMBL691162 | 0.90 | PTGER4 (0.65) | PTGER4PTGER2MRGPRX4PTGDRPTGER1 | |
| SCHEMBL22076508 | 0.90 | PTGER4 (0.65) | PTGER4PTGER2MRGPRX4PTGDRPTGER1 | |
| SCHEMBL4564952 | 0.89 | PTGER4 (0.63) | PTGER4PTGER2PTGDRPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253595-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | ASKAT INC. (JP) | 2017-09-07 | — | — | US | claimed |
| US-20120088723-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | RAQUALIA PHARMA INC. (JP) | 2012-04-12 | — | — | US | claimed |
| EP-2422779-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | RaQualia Pharma Inc (JP) | 2012-02-29 | — | — | EP | claimed |
| EP-1756043-B1 | ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS | RAQUALIA PHARMA INC (JP) | 2009-07-01 | — | — | EP | claimed |
| EP-1756043-A1 | ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| US-20050250818-A1 | Ortho substituted aryl or heteroaryl amide compounds | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| WO-2005105733-A1 | ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2005-11-10 | — | — | WO | claimed |
| US-11840530-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | ASKAT INC. (JP) | 2023-12-12 | — | — | US | disclosed |
| US-20220073510-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | ASKAT INC. (JP) | 2022-03-10 | — | — | US | disclosed |
| US-10947235-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | ASKAT INC. (JP) | 2021-03-16 | — | — | US | disclosed |
| US-20200188367-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | ASKAT INC. (JP) | 2020-06-18 | — | — | US | disclosed |
| US-10611761-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | ASKAT INC. (JP) | 2020-04-07 | — | — | US | disclosed |
| EP-3431085-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | AskAt Inc. (JP) | 2019-01-23 | — | — | EP | disclosed |
| WO-2005102389-A9 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1756043-A1 | ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1740211-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050250818-A1 | Ortho substituted aryl or heteroaryl amide compounds | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| WO-2005105733-A1 | ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947235-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885MRGPRX4 35/4885 |
| US-20170253595-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885MRGPRX4 37/4885 |
| US-20220073510-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885MRGPRX4 35/4885 |
| US-11840530-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885MRGPRX4 35/4885 |
| US-20120088723-A1 | SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885MRGPRX4 33/4885 |
| US-20200188367-A1 | SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885MRGPRX4 35/4885 |
| US-20050250818-A1 | Ortho substituted aryl or heteroaryl amide compounds | OPRL1, PTGER1, OPRM1 | PTGER4 19/4885PTGER2 6/4885MRGPRX4 105/4885 |
| US-10611761-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885MRGPRX4 37/4885 |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | PTGER4 1/4885PTGER2 2/4885MRGPRX4 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.